Publications

CendR Platform® Technology

Population Pharmacokinetic Modeling of Certepetide in Human Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

Winning, A., Sietsema, W.K., Buck, K.K., Linsmeier, A. and Wiczling, P. (2025), Population Pharmacokinetic Modeling of Certepetide in Human Subjects With Metastatic Pancreatic Ductal Adenocarcinoma. Clin Pharmacol Drug Dev. https://doi.org/10.1002/cpdd.1502

LSTA1 Potentiates Complete Response in Metastatic Gastroesophageal Adenocarcinoma

Buck, K.K, Dean, A., McSweeney, T. LSTA1 Potentiates Complete Response in Metastatic Gastroesophageal Adenocarcinoma. Oncol Cancer Case Rep. 2023, 9(6), 001-003

ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with Certepetide in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial

Dean A., et al. ESMO Gastrointestinal Oncology. 2023; https://doi.org/10.1016/j.esmogo.2023.07.001

A phase Ib/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics/pharmacodynamics of αvβ3/5 integrin and neuropilin-1 targeting peptide Certepetide in patients with metastatic pancreatic ductal adenocarcinoma.

J Clin Oncol 41, 2023 (suppl 16; abstr e16290)

Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study

Dean A., et al. The Lancet Gastroenterology and Hepatology. 2022; https://doi.org/10.1016/S2468-1253(22)00167-4

Tumor Microenvironment-Responsive Polymeric iRGD and Doxorubicin Conjugates Reduce Spontaneous Lung Metastasis in an Orthotopic Breast Cancer Model

Peng Z-H, Jogdeo CM, Li J, Xie Y, et al. Pharmaceutics. 2022; 14(8):1725. https://doi.org/10.3390/pharmaceutics14081725

Nature Communications: Tumor-penetrating therapy for ß5 integrin-rich pancreas cancer

Hurtado de Mendoza, T., Mose, E.S., Botta, G.P. et al. Nat Communications 12, 1541. 2021; https://doi.org/10.1038/s41467-021-21858-1

Cancer Research: Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies

Fan Zhang, Sirkka B. Stephan, et al. Cancer Res. 2018; 78 (13): 3718–3730. https://doi.org/10.1158/0008-5472.CAN-18-0306

The Journal of Clinical Investigation: Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer

Liu X, Lin P, Perrett I, et al. J Clin Invest. 2017;127(5):2007-2018. doi: 10.1172/JCI92284

Advanced Drug Delivery Reviews: Tumor penetrating peptides for improved drug delivery

Ruoslahti E. Adv Drug Deliv Rev. 2017;110-111:3-12. doi: 10.1016/j.addr.2016.03.008

Nature Communications: In vivo cation exchange in quantum dots for tumor-specific imaging

Liu, X., Braun, G.B., Qin, M. et al. Nat Communications 8, 343. 2017. https://doi.org/10.1038/s41467-017-00153-y

Cancer Research: Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma

Christian Schmithals, Verena Köberle, et al. Cancer Res. 2015; 75 (15): 3147–3154. https://doi.org/10.1158/0008-5472.CAN-15-0395

British Journal of Cancer: Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1

Akashi, Y., Oda, T., et al. British journal of cancer, 110(6), 1481–1487. 2014. https://doi.org/10.1038/bjc.2014.49

Science: Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs

Ruoslahti E, et al. Science. 2010; 28, 5981. doi: 10.1126/science.1183057

CendR Platform® Technology Related

Pancreatic cancer: failures and hopes—a review of new promising treatment approaches

Cereda, V., & D’Andrea, M. R. (2025). Pancreatic cancer: failures and hopes-a review of new promising treatment approaches. Exploration of targeted anti-tumor therapy, 6, 1002299. https://doi.org/10.37349/etat.2025.1002299

Integrins in Cancer Drug Resistance: Molecular Mechanisms and Clinical Implications

Kariya, Y., & Nishita, M. (2025). Integrins in Cancer Drug Resistance: Molecular Mechanisms and Clinical Implications. International Journal of Molecular Sciences, 26(7), 3143. https://doi.org/10.3390/ijms26073143

Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma

Demir, T., Moloney, C., & Mahalingam, D. (2025). Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma. Cancers, 17(5), 715. https://doi.org/10.3390/cancers17050715

Exploration of tumor penetrating peptide iRGD as a potential strategy to enhance tumor penetration of cancer nanotherapeutics

Saifi, M. A., Sathish, G., Bazaz, M. R., & Godugu, C. (2023). Exploration of tumor penetrating peptide iRGD as a potential strategy to enhance tumor penetration of cancer nanotherapeutics. Biochimica Et Biophysica Acta (BBA) – Reviews on Cancer, 1878(3), 188895. https://doi.org/10.1016/j.bbcan.2023.188895

Research Progress on Cyclic-Peptide Functionalized Nanoparticles for Tumor-Penetrating Delivery

Wang, C., et al. (2024) International Journal of Nanomedicine, Volume 19, 12633–12652. https://doi.org/10.2147/ijn.s487303

Enhancing Tumor Targeted Therapy: The Role of iRGD Peptide in Advanced Drug Delivery Systems

Nikitovic, D., et al. Cancers 2024,16(22), 3768. https://doi.org/10.3390/cancers16223768

Biomimetic nanocarriers in cancer therapy: based on intercellular and cell-tumor microenvironment communication

Mengyuan, H., Aixue, L., Yongwei, G. et al. J Nanobiotechnol 22, 604 (2024). https://doi.org/10.1186/s12951-024-02835-4

Tumour-specific activation of a tumour-blood transport improves the diagnostic accuracy of blood tumour markers in mice

Christian Schmithals, et al. Tumour-specific activation of a tumour-blood transport improves the diagnostic accuracy of blood tumour markers in mice. EBioMedicine. Vol 105 July, 2024

Current and future immunotherapeutic approaches in pancreatic cancer treatment

Farhangnia, P., Khorramdelazad, H., Nickho, H. et al. J Hematol Oncol 17, 40 (2024).

Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC

Musiu C, Lupo F, et al. (2024) Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC. Front. Immunol. 15:1341079. doi: 10.3389/fimmu.2024.1341079

Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date

Storandt MH, Jin Z, Mahipal A. Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date. Onco Targets Ther. 2024;17:383-394

Overall survival and treatment modalities in pancreatic adenocarcinoma: a retrospective analysis of a single centre in Western Australia

Talbot A, et al. J Gastrointest Oncol 2023;14(5):2221-2228. doi: 10.21037/jgo-23-488

The role of TNC in atherosclerosis and drug development opportunities

Chen, W., et al. (2024). The role of TNC in atherosclerosis and drug development opportunities. International Journal of Biological Sciences, 20(1), 127-136. https://doi.org/10.7150/ijbs.89890.

RGD-Binding Integrins in Head and Neck Cancers

Ahmedah HT, et al. RGD-Binding Integrins in Head and Neck Cancers. Cancers (Basel). 2017 May 26;9(6):56. doi: 10.3390/cancers9060056. PMID: 28587135; PMCID: PMC5483875.

Molecular View on the iRGD Peptide Binding Mechanism: Implications for Integrin Activity and Selectivity Profiles

D’Amore VM, et al. Molecular View on the iRGD Peptide Binding Mechanism: Implications for Integrin Activity and Selectivity Profiles. J Chem Inf Model. 2023 Oct 23;63(20):6302-6315. doi: 10.1021/acs.jcim.3c01071. Epub 2023 Oct 3. PMID: 37788340; PMCID: PMC10598797.